A J Butt

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi The IGF axis and programmed cell death
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    Immunol Cell Biol 77:256-62. 1999
  2. ncbi Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, New South Wales 2065, Australia
    J Biol Chem 275:39174-81. 2000
  3. ncbi IGFBP-3 and apoptosis--a license to kill?
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    Apoptosis 6:199-205. 2001
  4. ncbi IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    Endocrinology 143:2693-9. 2002
  5. ncbi Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Biol Chem 278:29676-85. 2003
  6. ncbi Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor
    S Fanayan
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Biol Chem 275:39146-51. 2000
  7. ncbi Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism
    Caroline G Roberts
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Mol Cancer Ther 6:2777-85. 2007
  8. ncbi c-Myc overexpression and endocrine resistance in breast cancer
    Catriona M McNeil
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010, Australia
    J Steroid Biochem Mol Biol 102:147-55. 2006
  9. ncbi A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, New South Vales 2010, Australia
    Mol Cancer Ther 5:2300-9. 2006
  10. ncbi Identification of downstream targets of estrogen and c-myc in breast cancer cells
    Elizabeth A Musgrove
    Cancer Research Program, Garvan Institute, Darlinghurst, Sydney, Australia
    Adv Exp Med Biol 617:445-51. 2008

Collaborators

Detail Information

Publications16

  1. ncbi The IGF axis and programmed cell death
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    Immunol Cell Biol 77:256-62. 1999
    ..This review summarizes what is currently known about the role of the IGF system in the regulation of apoptosis, highlighting its implications in the context of tumorigenesis...
  2. ncbi Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, New South Wales 2065, Australia
    J Biol Chem 275:39174-81. 2000
    ....
  3. ncbi IGFBP-3 and apoptosis--a license to kill?
    A J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    Apoptosis 6:199-205. 2001
    ..This review examines the current evidence for a pro-apoptotic function for IGFBP-3 and speculates on its physiological significance...
  4. ncbi IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    Endocrinology 143:2693-9. 2002
    ..This suggests the existence of multiple pathways by which IGFBP-3 elicits its growth effects...
  5. ncbi Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Biol Chem 278:29676-85. 2003
    ..These data suggest that IGFBP-5 is a potent growth inhibitor and proapoptotic agent in human breast cancer cells via modulation of cell cycle regulation and apoptotic mediators...
  6. ncbi Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor
    S Fanayan
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Biol Chem 275:39146-51. 2000
    ..These data suggest that IGFBP-3 inhibitory signaling requires an active TGF-beta signaling pathway and implicate Smad2 and Smad3 in IGFBP-3 signal transduction...
  7. ncbi Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism
    Caroline G Roberts
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Mol Cancer Ther 6:2777-85. 2007
    ....
  8. ncbi c-Myc overexpression and endocrine resistance in breast cancer
    Catriona M McNeil
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010, Australia
    J Steroid Biochem Mol Biol 102:147-55. 2006
    ....
  9. ncbi A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, New South Vales 2010, Australia
    Mol Cancer Ther 5:2300-9. 2006
    ..Due to the unique structure of the compound, persin could represent a novel class of microtubule-targeting agent with potential specificity for breast cancers...
  10. ncbi Identification of downstream targets of estrogen and c-myc in breast cancer cells
    Elizabeth A Musgrove
    Cancer Research Program, Garvan Institute, Darlinghurst, Sydney, Australia
    Adv Exp Med Biol 617:445-51. 2008
    ..These data indicate that a significant component of E-induced mitogenesis is mediated by c-myc and that selected c-myc target genes may be surrogate markers of c-myc expression in BC...
  11. ncbi Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royan North Shore Hospital, New South Wales 2065, Australia
    Endocrinology 146:3113-22. 2005
    ..Furthermore, although IGFBP-3 and IGFBP-5 share much structural and functional homology, they can modulate distinct apoptotic pathways in human breast cancer cells...
  12. ncbi Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling
    Alison J Butt
    Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Clin Endocrinol Metab 89:1950-6. 2004
    ....
  13. ncbi The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, St, Vincent s Hospital, Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Breast Cancer Res 10:R28. 2008
    ..Characterization of estrogen-target genes may help to elucidate further the mechanisms of estrogen-induced mitogenesis and endocrine resistance...
  14. ncbi Live or let die: oestrogen regulation of survival signalling in endocrine response
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, St, Vincent s Hospital, Darlinghurst, New South Wales, Australia
    Breast Cancer Res 9:306. 2007
    ..Thus, further elucidation of this process may lead to identification of clinically relevant end-points to determine and delineate therapeutic response in breast cancer patients...
  15. ncbi Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, New South Wales 2010, Australia
    Endocr Relat Cancer 12:S47-59. 2005
    ....
  16. ncbi Cell cycle machinery: links with genesis and treatment of breast cancer
    Alison J Butt
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
    Adv Exp Med Biol 630:189-205. 2008
    ..Furthermore, a more detailed understanding of these pathways may identify new targets for therapeutic intervention particularly in endocrine-unresponsive and endocrine-resistant disease...